PORTOLA VALLEY, Calif.--(BUSINESS WIRE)--TransMed7, LLC, today announced the appointment of Michael J. Demeure, MD, MBA, as Chair of its Endocrine and Gastrointestinal (GI) Health Team and Member of its Executive Team of TransMed7’s Clinical and Scientific Advisory Board (CSAB). "We are honored to have Dr. Demeure as Chair of our Endocrine and GI Health Team. Recognized as one of the top surgeons in the United States, Dr. Demeure is keenly interested in new transformational medical technologies that will help all physicians realize more precise diagnostic and therapeutic interventions,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO. “In his role, he will be responsible for leading TransMed7’s Endocrine and GI Health Team in achieving our goal of developing and rapidly fielding new minimally invasive medical technologies integrated with advanced imaging modalities, beginning with Cardinal™ - our new platform technology for fine-needle core biopsy procedures.”
Dr. Demeure is the Program Director for Precision Medicine at the Hoag Family Cancer Institute and a fellowship-trained endocrine surgeon with the Newport Irvine Surgical Specialists group. He is also an Adjunct Professor at the Translational Genomics Research Institute (TGen), and previously a Clinical Professor of Surgery at the University of Arizona, College of Medicine in Phoenix, AZ. Dr. Demeure is a 1983 graduate of Hahnemann Medical College and completed his surgical residency at the University of Arizona. He subsequently completed a fellowship in endocrine surgery in Perth, Australia and at the University of California, San Francisco. He previously held faculty positions at the Medical College of Wisconsin, as Professor and Chief of General Surgery at the University of Arizona, and most recently as Scientific Director, Center for Pancreatic and Endocrine Surgery, Scottsdale Healthcare and Professor and Director of the Rare Tumors Program in the Division of Integrated Cancer Genomics at TGen. In 2007, Dr. Demeure completed his MBA at the University of Arizona.
Dr. Demeure is an internationally recognized expert in cancer surgery and research with particular expertise in endocrine, pancreatic and gastrointestinal cancers. In addition to a very active clinical practice, Dr. Demeure has led a highly productive research lab for over 20 years focused on using genomic technologies to develop novel biomarkers, new therapeutic targets, and related therapies in the management of endocrine and gastrointestinal cancers; this has led to his being the Co- or Principle Investigator on several of the landmark trials in these same areas. Dr. Demeure is the author or co-author of over 100 scholarly works and he has given over 150 invited lectures and presentations. Dr. Demeure is a past-President of the American Association of Endocrine Surgeons, is regularly recognized as one of “America’s Top Surgeons” and has been named as one of the “Best Doctors in America” every year since 2001. Prior to his move to the Hoag Family Cancer Institute at Hoag Hospital, he helped TGen with the launch and direction of Ashion Analytics, a commercial clinical sequencing lab serving as its Chief Medical Officer, Executive Vice-President and General Manager.
“I am delighted to be joining TransMed7’s talented and enthusiastic team of clinicians, scientists, and engineers in developing and implementing new breakthrough diagnostic and therapeutic technologies for the benefit of patients everywhere,” said Dr. Demeure.
According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Demeure brings valuable leadership experience in the rapidly expanding field of precision medicine and distinctive expertise in endocrine and gastrointestinal diseases. We look forward to his guidance as we build on our strengths in the field of image-guided, minimal access intervention to rapidly make a difference in the lives of patients in need.”
About TransMed7, LLC
TransMed7, LLC is a medical and technology based organization focused on the highly efficient development of innovative, minimally invasive medical devices aimed at providing new solutions for doctors and their patients. With particular expertise in both oncologic and cardiovascular disease, TransMed7 and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices that are expected to be market leaders in their targeted fields of medicine. TransMed7 accomplishes this through application of a wholly new approach in its business plan and structure, enabling these new transformational technologies from rapid development through commercial manufacturing or where appropriate, handoff to our Strategic Partners. For more information about TransMed7, please visit our website at www.transmed7.com.